Exemestane in the prevention setting

Jennifer Keating Litton; Banu K. Arun; Therese B. Bevers

doi:10.1177/1758834012438214

Exemestane in the prevention setting

Jennifer Keating Litton, Banu K. Arun, Therese B. Bevers

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.

Original language	English (US)
Pages (from-to)	107-112
Number of pages	6
Journal	Therapeutic Advances in Medical Oncology
Volume	4
Issue number	3
DOIs	https://doi.org/10.1177/1758834012438214
State	Published - May 2012

Keywords

aromatase inhibitors
breast cancer
exemestane
prevention

ASJC Scopus subject areas

Oncology

Access to Document

10.1177/1758834012438214

Cite this

@article{580639e226994ee7a51e81024fb2cc8a,

title = "Exemestane in the prevention setting",

abstract = "Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.",

keywords = "aromatase inhibitors, breast cancer, exemestane, prevention",

author = "Litton, {Jennifer Keating} and Arun, {Banu K.} and Bevers, {Therese B.}",

year = "2012",

month = may,

doi = "10.1177/1758834012438214",

language = "English (US)",

volume = "4",

pages = "107--112",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

number = "3",

}

TY - JOUR

T1 - Exemestane in the prevention setting

AU - Litton, Jennifer Keating

AU - Arun, Banu K.

AU - Bevers, Therese B.

PY - 2012/5

Y1 - 2012/5

N2 - Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.

AB - Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.

KW - aromatase inhibitors

KW - breast cancer

KW - exemestane

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=84864439172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864439172&partnerID=8YFLogxK

U2 - 10.1177/1758834012438214

DO - 10.1177/1758834012438214

M3 - Review article

C2 - 22590484

AN - SCOPUS:84864439172

SN - 1758-8340

VL - 4

SP - 107

EP - 112

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

IS - 3

ER -

Exemestane in the prevention setting

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this